219 related articles for article (PubMed ID: 37543290)
21. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
[TBL] [Abstract][Full Text] [Related]
22. RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.
Saunders PO; Weiss J; Welschinger R; Baraz R; Bradstock KF; Bendall LJ
Oncogene; 2013 Oct; 32(40):4789-97. PubMed ID: 23128395
[TBL] [Abstract][Full Text] [Related]
23. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
24. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
25. Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia.
Bride KL; Hu H; Tikhonova A; Fuller TJ; Vincent TL; Shraim R; Li MM; Carroll WL; Raetz EA; Aifantis I; Teachey DT
Haematologica; 2022 Aug; 107(8):1746-1757. PubMed ID: 34937317
[TBL] [Abstract][Full Text] [Related]
26. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
Sarris AH; Hagemeister F; Romaguera J; Rodriguez MA; McLaughlin P; Tsimberidou AM; Medeiros LJ; Samuels B; Pate O; Oholendt M; Kantarjian H; Burge C; Cabanillas F
Ann Oncol; 2000 Jan; 11(1):69-72. PubMed ID: 10690390
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.
Li Z; Younger K; Gartenhaus R; Joseph AM; Hu F; Baer MR; Brown P; Davila E
J Clin Invest; 2015 Mar; 125(3):1081-97. PubMed ID: 25642772
[TBL] [Abstract][Full Text] [Related]
28. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
29. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
Minson KA; Smith CC; DeRyckere D; Libbrecht C; Lee-Sherick AB; Huey MG; Lasater EA; Kirkpatrick GD; Stashko MA; Zhang W; Jordan CT; Kireev D; Wang X; Frye SV; Earp HS; Shah NP; Graham DK
JCI Insight; 2016 Mar; 1(3):e85630. PubMed ID: 27158668
[TBL] [Abstract][Full Text] [Related]
30. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Henze G; v Stackelberg A; Eckert C
Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
[TBL] [Abstract][Full Text] [Related]
31. Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells.
Siqueira RP; Caetano MMM; de Souza LÂ; Dos Passos PMS; Simaroli NB; Barros MVA; de Souza APM; de Oliveira LL; Silva-Júnior A; Fietto JLR; Teixeira RR; Teixeira FR; Bressan GC
Toxicol In Vitro; 2020 Jun; 65():104777. PubMed ID: 31962201
[TBL] [Abstract][Full Text] [Related]
32. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
33. B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow.
Barz MJ; Behrmann L; Capron D; Zuchtriegel G; Steffen FD; Kunz L; Zhang Y; Vermeerbergen IJ; Marovca B; Kirschmann M; Zech A; Nombela-Arrieta C; Ziegler U; Schroeder T; Bornhauser B; Bourquin JP
Haematologica; 2023 May; 108(5):1244-1258. PubMed ID: 36325888
[TBL] [Abstract][Full Text] [Related]
34. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B; Sanchéz-Martínez D; Roca-Ho H; Gutiérrez-Agüera F; Molina O; Diaz de la Guardia R; Torres-Ruiz R; Fuster JL; Ballerini P; Suessbier U; Nombela-Arrieta C; Bueno C; Menéndez P
Leukemia; 2019 Jul; 33(7):1557-1569. PubMed ID: 30635633
[TBL] [Abstract][Full Text] [Related]
35. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.
Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB
Oncotarget; 2016 Sep; 7(37):58728-42. PubMed ID: 27623214
[TBL] [Abstract][Full Text] [Related]
37. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
[TBL] [Abstract][Full Text] [Related]
39. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
40. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
